Although the global pulmonary drug delivery market is now so large that many players can profitably coexist for some time, as regulation evolves in order to push improvements and establish a baseline in inhaler performance, the optimal strategy is to innovate. Innovation allows the creation of new and better inhalers which can specifically address problems inherent in inhaler design, and David Harris of Team Consulting looks into the key drivers – commercial, technological and regulatory – fuelling current advances.
https://international-pharma.com/wp-content/uploads/2014/03/Beyond-asthma…pdf.pdf